Medical Devices and the False Claims Act: Proving the Claim Beyond the FDA Violation

A medical device False Claims Act case connects a company’s knowing misconduct to a false claim for government payment. You may know why surgeons changed products, what a quality team concealed, or who supplied the billing instructions. The hospital may send the bill, but the decision that made it false can begin inside the manufacturer.

Can a Whistleblower Take Legal Action Against a Medical Device Company?

Yes. A manufacturer can face a False Claims Act case for knowingly causing a hospital or physician to submit false claims. Device cases can involve off-label marketing, kickbacks, defective products, false billing instructions or replacement credits missing from a hospital’s claim.

In its 2016 civil settlement announcement about Acclarent, the Justice Department alleged that the company marketed and distributed a sinus spacer for use as a drug delivery device without Food and Drug Administration approval for that use, causing providers to submit claims to Medicare and other federal health care programs.

A whistleblower brings a qui tam case on the government’s behalf. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

How Does Reimbursement Work for Medical Devices?

Medicare usually pays for an implanted device within the hospital’s payment for a procedure or stay. The manufacturer sells the device to the institution, while the physician may make or strongly influence the product choice. The Department of Health and Human Services’ Office of Inspector General describes implants as physician preference items in its alert on physician-owned entities.

Consignment makes that split especially concrete. The hospital can have an implant on its shelf while the manufacturer still owns it. Use or implantation can trigger the sale. A representative may manage the inventory, deliver instruments and support the surgeon’s use of the system. The product choice, the manufacturer’s revenue and the hospital’s claim meet around the same procedure.

An outpatient claim can carry a device code and charge even when Medicare includes the device’s cost in the procedure payment. The inpatient system generally includes it in the payment for the stay. That puts the hospital’s procedure, admission and payment records beside the manufacturer’s invoice when we examine a device case.

The person who knows what was sold and the person who knows what was billed may work for different businesses. Connecting their records is how the commercial story becomes a payment story.

What Qualifies as a Whistleblower Complaint?

A medical device whistleblower complaint connects knowing misconduct to a false claim for government money. A quality complaint can show what the company knew, a sales instruction can show how it influenced product use, and the provider’s claim shows what reached the payer.

The government’s decision to pay matters, too. In its decision involving Universal Health Services, the Supreme Court explained that specific statements about goods or services can become misleading when important noncompliance is concealed. The claim can tell a half-truth about what the government bought. We work through that connection with you, drawing on what you know about the product and the business behind it.

FDA Authorization and the Product the Government Paid For

Quality and regulatory records can show a gap between the product authorized for sale and the product supplied to patients. That gap was central to the allegations about DePuy Orthopaedics’ Pinnacle metal-on-metal hip in a 2017 court decision. The court allowed the defective-device claims to proceed in 2017, but upheld the case’s dismissal in 2023 for repeated violations of court confidentiality orders, without deciding those claims.

The whistleblowers alleged that the hips actually sold departed from the cleared specifications. Doctors allegedly received products with hidden defects and sought government reimbursement without knowing of those defects. The alleged result was defective hips for patients and government payment for their use.

The defects allegedly remained hidden during surgery, so a claim could reach the government before the problem became apparent. That puts manufacturing and clinical records on the same timeline: the specifications, test results and complaint history beside the operative record and billing date.

The ev3 case concerned its Onyx Liquid Embolic System and Axium Detachable Coil System. The whistleblower alleged that ev3 obtained Onyx approval through false representations to the Food and Drug Administration. The court’s decision turned on the missing connection between those representations and the agency’s approval. What the manufacturer submitted and how the agency responded are questions we examine with regulatory insiders.

The First and Ninth Circuits illustrated product substitution with a hypothetical from a drug case: a claim sought payment for Atripla while the company supplied Tylenol. For devices, the comparable inquiry concerns the authorized specifications, the product actually supplied and the description that supported payment.

Coverage, Coding and the Product Actually Used

Coverage conditions and billing descriptions provide other connections between device conduct and government payment. Food and Drug Administration authorization, Medicare coverage, a billing code and the amount paid each answer a different question.

The Medicare law’s coverage rules require covered care to be reasonable and necessary. The Prometheus Group case put the manufacturer’s instructions to providers directly into that inquiry.

In its civil complaint announcement, the Justice Department alleged that Prometheus instructed providers to reuse rectal pressure sensors and anorectal manometry catheters across patients, covering the probes with a glove or condom to reduce costs. The sensors were restricted to a single user, and the catheters to a single use.

The government alleged that reuse exposed patients to infection risks and made the services ineligible for Medicare coverage. It also alleged that Prometheus had made no attempt to establish whether the probes worked effectively under those conditions. The manufacturer and its owner agreed to pay $550,000 to settle the civil allegations in 2025. The alleged savings came from reusing probes on patients while Medicare paid for services the government said were unsafe.

Stimwave supplies a particularly concrete coding example. In the $8.6 million civil settlement described in the Justice Department’s announcement of criminal charges against Stimwave’s former chief executive, the company admitted presenting an inert plastic component as a functioning receiver. Providers implanted it and used an additional Medicare reimbursement code. The government was billed for implanting a receiver that did not receive anything.

Replacement credits present another payment question. A manufacturer may supply a replacement free or issue a credit, while the hospital submits a claim for the replacement procedure. The credit memo, the hospital’s receipt of it and the applicable payment adjustment connect the manufacturer’s transaction to Medicare’s bill. The device’s cost can affect the amount due even within a bundled payment.

What Evidence Is Needed to Prove Fraud?

The evidence connects what the company represented, what it knew, what the provider did and what the government paid for. Sales, quality, regulatory and reimbursement staff can each see a part of that connection.

A 2020 article in the Journal of Forensic and Investigative Accounting, A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud, explains why investigators need evidence for each part of the alleged offense. In a device case, that can mean connecting records held by the manufacturer with records held by the hospital.

The significance of an internal record becomes clearer when it is placed beside the transaction it describes. A surgeon payment beside that surgeon’s product use answers a different question from the payment alone. A failed test beside the specification promised to customers shows what the company was selling with that result in hand.

What Are Some Examples of Kickbacks in Healthcare?

Device kickback cases involve consulting fees, royalties, grants, free services and other benefits used to induce product selection. The connection to federal payment runs through the resulting items or services.

A physician-owned distributor can put the surgeon on both sides of a device purchase. The inspector general describes entities that earn revenue from implants their physician owners order for procedures on their own patients. The hospital buys a product chosen by someone who shares in the seller’s revenue.

The financial records can show whether distributions follow invested capital or the owner’s own cases, and whether continued ownership depends on product use. Those details connect the return to the purchasing decision. We examine the ownership terms, distribution records and implant orders alongside the provider claims that followed.

The whistleblower complaint against Life Spine described consulting arrangements whose real demand was product use:

Life Spine later agreed to pay $5.5 million and admitted in its settlement that management reports compared surgeon payments with product use. One report calculated return on investment from sales associated with a surgeon against the consulting fees and royalties paid to that surgeon. Senior sales managers pressed surgeons to increase use when it fell. The company measured the return in implants.

For someone in sales or finance, that makes the compensation agreement, management report and implant orders parts of the same story. The provider records then connect those implant decisions to federal claims.

What the Company Knew Before It Sold the Device

Internal warnings can put a company’s knowledge into its own chronology. Instrumed’s quality and regulatory leader wrote that the company could not claim an exemption for devices marketed before Food and Drug Administration clearance requirements began because Instrumed had not marketed the device then. Its distributor, CareFusion, also repeatedly challenged the supporting evidence.

In the $9.5 million settlement involving Instrumed and Avalign Technologies in 2019, the companies admitted conduct involving sales of uncleared instruments under that claimed exemption. Instrumed continued selling after the internal warning, the distributor’s objections and a Food and Drug Administration warning letter.

Distributors can also face a case. In its separate civil settlement, CareFusion admitted buying and selling instruments without the required approval or clearance. It also admitted that the manufacturer’s evidence for the exemption was insufficient.

Those records connect what regulatory staff knew to what the business continued to sell. In a defective-product case, test results, complaint investigations and changes to the device serve a similar purpose when placed beside customer representations and product use.

How Is Medicare Fraud Detected?

Device investigations connect hospital and manufacturer records to claims and payment data. Ordinary hospital claims can omit the particular implant’s identity, leaving the operative record, product identifiers and manufacturer records to supply that detail.

Product identifiers connect the device used to its manufacturing and complaint history. The operative record connects it to the patient and procedure. Billing records identify what the provider represented to the payer, while replacement and credit records explain later adjustments. We examine those connections with the insider who knows why the records look the way they do.

Durable Medical Equipment and Diagnostic Devices

The False Claims Act also reaches durable medical equipment and diagnostic devices. Durable medical equipment can be billed as a separate item, putting the supplier’s claim at the center of the payment story.

The Justice Department’s ResMed settlement concerned alleged inducements connected to sales of sleep apnea equipment, including free services and discounted equipment. Its Alere settlement over point-of-care tests concerned allegedly selling unreliable diagnostic devices despite knowing of the problems. The product changes, but the connection between sales conduct, internal knowledge and government payment remains.

When the Government Buys the Equipment Directly

Direct federal procurement puts the government’s own purchase at the center of the case. Illumina agreed to a $9.8 million settlement in July 2025 over allegations involving cybersecurity weaknesses and inadequate quality and security processes in genomic sequencing systems sold to federal agencies, coupled with false representations of standards compliance.

Here the relevant transaction was the sale to the agency. The product’s condition and the representations attached to that purchase supplied the connection to government money.

How We Help Medical Device Insiders

If you know how a device company’s sales instructions, quality decisions or reimbursement advice reached a government bill, speak with our whistleblower experts about that connection. We build your strongest medical device whistleblower case with you, bring in medical device whistleblower lawyers who understand manufacturer-caused claims, and stay beside you through the process.